Collaborations among academic and government researchers, pharmaceutical and biotechnology companies, regulatory agencies, and patients and their families are crucial to research and development of therapeutics for rare diseases. Industry, academic and government researchers, regulatory agencies, patients and their caregivers all confront challenges in today’s environment for therapeutic development. As a result, the stakeholders are realizing the increasing value in collaborations, which can help tackle these challenges.